Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Aktis Oncology

Explore full profile

Biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals

Boston, United StatesFounded 2020Biotech & Life Sciences
Valuation $692M Market cap · 2026
Revenue $11M Latest reported FY
Total funding $100–500M Disclosed equity funding

About Aktis Oncology

Aktis Oncology is a pioneering biotech company focused on developing novel radiotherapies for cancer patients with unmet medical needs. Operating in the oncology market, Aktis targets a broad set of commonly occurring cancers, aiming to revolutionize cancer treatment by putting solid tumors into remission. The company serves patients who have limited treatment options, providing them with innovative therapeutic solutions.

Read full description

Aktis Oncology's business model revolves around the research, development, and commercialization of transformative cancer therapies. The company generates revenue through the development and licensing of its proprietary radiotherapy molecules, as well as potential partnerships with pharmaceutical companies. By focusing on groundbreaking science and clinical development, Aktis aims to bring new hope to cancer patients worldwide.

Source: Dealroom company data

At a glance

Founded
2020
Headquarters
Boston, United States
Listing
IPO 2026
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Latest news

Press, funding announcements and product moves mentioning Aktis Oncology.

See all news

Investors

15 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A14 investors entered at this stage

  • MPM BioImpact
  • EcoR1 Capital
  • Vida Ventures
  • Novartis
  • Bristol-Myers Squibb
  • Octagon Capital Partners
  • TCGX
  • MRL Ventures
  • ArrowMark Partners
  • Timefolio Capital
  • Eli Lilly
  • RA Capital Management
  • RTW Investments
  • Janus Henderson Investors

Series B and later1 investor entered at this stage

  • Avidity Partners

Talent

Book a demo to see the people
Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States98.8%
🇨🇦 Canada1.3%
2 countries shown
Web traffic by country
6.1K monthly visits
across markets
🇺🇸 United States88.5%
🇮🇳 India11.5%
Top 2 markets shown

Patents

Estimated portfolio value
$78k

5 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Aktis Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Aktis Oncology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles